Anavex Life Sciences Corp (AVXL)

[georgejjl]

Anavex’s patent will be expected to remain in force at least until October 2036, not including any patent term extensions. The patent will expand the coverage of certain ANAVEX®2-73 (blarcamesine) crystals covered by U.S. Patent No. 10,413,519, to methods of their making. The ANAVEX®2-73 (blarcamesine) compound in one of its crystal forms has been used in various preclinical and clinical trials, for a broad range of CNS disorders, including but not limited to, Alzheimer’s disease, Parkinson’s disease, Parkinson’s disease dementia, Rett syndrome, Fragile X syndrome, Infantile spasms, Angelman syndrome and other undisclosed rare CNS disorders.

https://www.anavex.com/post/anavex-announces-new-u-s-intellectual-property-compositions-patent-for-anavex-2-73-blarcamesine

Good luck and GOD bless,